Goldman thinks the market is underestimating the odds of a faster-than-expected coronavirus vaccine

Scientist Xinhua Yan works in the lab at Moderna in Cambridge, MA on Feb. 28, 2020. Moderna has developed the first experimental coronavirus medicine, but an approved treatment is more than a year away.Markets underappreciate the rising odds of a Covid-19 vaccine and are failing to price in the better chances of an FDA-approved inoculation by the end of November, Goldman Sachs told clients.

Goldman cited revised projections from consulting firm Good Judgment, which in early June saw less than a 10% chance of a vaccine being "broadly available" by the end of March 2021, now it puts that chance at nearly 40%. Goldman said Wednesday it agrees with those findings, telling clients "there is a good chance that at least one vaccine will be FDA-approved by the end of November and broadly distributed by the middle of 2021."Related Tags

Pro Even if there is one, just imagine how long it’s going to take to get it to everyone. Imagine the debate around tracing whether enough people have gotten it. Imagine the response of anti vax people and the question of what to do about that. Imagine how much time that will take.

Pro I don't care for Goldman .

Pro Prophecy of Judgement & Wrath of God The Messiah is Coming Lets Repent & Turn Away from sin

Pro Goldman Suchs

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Big Tech is 'richly priced' — but investors will need it to beat the market, Prof Damodaran says | Markets InsiderAswath Damodaran, professor of finance at NYU Stern School of Business, told CNBC that big tech is 'richly priced.'  Often referred to as t... That’s it right there, outperforming indices (“the markets”) when big tech weighs so heavy requires even overweighing that same big tech, thus becoming a self sustaining circle, no escape
Source: BusinessInsider - 🏆 729. / 51 Read more »